NCT05633914View on ClinicalTrials.gov

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions

HR+/HER2- Breast Cancer

Interventions

DRUG

Tucidinostat

20mg, po., biw, q3w

DRUG

nab-paclitaxel

125mg/m2, d1, iv.drip, q7d

Trial Locations (1)

Unknown

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Hunan Cancer Hospital

OTHER